Lenacapavir (LEN) is a new option to help prevent HIV. This study is looking at how people use LEN in real life. **Pre-exposure prophylaxis (PrEP)** means taking medicine to prevent getting HIV before being exposed. This study checks how long people stick with using LEN over a year (52 weeks). Participants need to be HIV-negative and interested in learning about PrEP options. They can be new to PrEP or have used other PrEP medicines like Truvada® or Descovy®. People can choose to use LEN or other PrEP options after learning about them. Participants must understand and agree to the study rules and be willing to follow them. There are some reasons (not listed) that might make someone unable to join. The study will give us more data on how effective LEN is for different people in the United States.

• Study lasts for 52 weeks.
• Participants must discuss and choose their PrEP method.
• Participants need to be HIV-negative and willing to follow study rules.